Abivax (ABVX) Amortization (2024 - 2025)
Abivax (ABVX) recorded quarterly Amortization of $111.7 million in Q2 2025, down 26.35% quarter-over-quarter from $151.7 million in Q1 2025, and down 8.47% on a YoY basis from $122.1 million in Q2 2024.
Abivax (ABVX) Amortization (2024 - 2025) Analysis & Trends
Abivax's Amortization history runs 2 years deep, the most recent figure standing at $111.7 million for Q2 2025.
- In Q2 2025, Amortization fell 8.47% year-over-year to $111.7 million; the TTM figure through Jun 2025 stood at $111.7 million (down 8.47% YoY), while the FY2024 annual figure was $116.7 million, changed N/A from the prior year.
- Amortization was $111.7 million for Q2 2025 at Abivax, down from $151.7 million in the prior quarter.
- In the past five years, Amortization ranged from a high of $151.7 million in Q1 2025 to a low of $104.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 111.73 Mn |
| Jun 30, 2025 | 111.73 Mn |
| Mar 31, 2025 | 151.70 Mn |
| Mar 31, 2025 | 151.70 Mn |
| Dec 31, 2024 | 116.71 Mn |
| Dec 31, 2024 | 116.71 Mn |
| Jun 30, 2024 | 122.08 Mn |
| Jun 30, 2024 | 122.08 Mn |
| Mar 31, 2024 | 104.41 Mn |
| Mar 31, 2024 | 104.41 Mn |